51
|
Xu Y, Jiang WG, Wang HC, Martin T, Zeng YX, Zhang J, Qi YS. BDNF activates TrkB/PLCγ1 signaling pathway to promote proliferation and invasion of ovarian cancer cells through inhibition of apoptosis. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2020; 23:5093-5100. [PMID: 31298409 DOI: 10.26355/eurrev_201906_18173] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Abnormal expression and activation of tropomyosin-related kinase receptor B (TrkB) are observed in many pathological conditions, including many types of cancer. We try to explore the relationship between ovarian cancer and Brain-derived neurotrophic factor (BDNF), a ligand of TrkB. MATERIALS AND METHODS Human ovarian cancer cell line SKOV-3 was used in this study. qPCR, immunohistochemistry, and immunoblot were used to assay BDNF and TrkB expression level. Scratch assay was used to test the cell motility, and transwell assay was used to test the cell migration ability. RESULTS We found that BDNF promotes the proliferation and invasion of human ovarian cancer SKOV-3 cells depend on the activation of TrkB. To illuminate the downstream pathway of BDNF/TrkB, we silenced AKT1 and PLCγ1 by siRNA. The functional assay showed that activated PLCγ1 signaling pathway is necessary for the proliferation and invasion of cancer cells other than the AKT pathway. Further study showed that PLCγ1 could inhibit the apoptosis of cancer cells. CONCLUSIONS BDNF triggers TrkB/PLCγ1 signaling pathway to promote proliferation and invasion of ovarian cancer cells through inhibition of apoptosis.
Collapse
|
52
|
Rech J, Jonckheere T, Grémaud B, Martin T. Negative Delta-T Noise in the Fractional Quantum Hall Effect. PHYSICAL REVIEW LETTERS 2020; 125:086801. [PMID: 32909784 DOI: 10.1103/physrevlett.125.086801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Accepted: 07/28/2020] [Indexed: 06/11/2023]
Abstract
We study the current correlations of fractional quantum Hall edges at the output of a quantum point contact subjected to a temperature gradient. This out-of-equilibrium situation gives rise to a form of temperature-activated shot noise, dubbed delta-T noise. We show that the tunneling of Laughlin quasiparticles leads to a negative delta-T noise, in stark contrast with electron tunneling. Moreover, varying the transmission of the quantum point contact or applying a voltage bias across the Hall bar may flip the sign of this noise contribution, yielding signatures that can be accessed experimentally.
Collapse
|
53
|
Lee BI, LaRue SM, Seguin B, Griffin L, Prebble A, Martin T, Leary D, Boss MK. Safety and efficacy of stereotactic body radiation therapy (SBRT) for the treatment of canine thyroid carcinoma. Vet Comp Oncol 2020; 18:843-853. [PMID: 32515526 DOI: 10.1111/vco.12625] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Revised: 06/01/2020] [Accepted: 06/02/2020] [Indexed: 01/12/2023]
Abstract
Thyroid carcinoma develops spontaneously in dogs, with only 25% to 50% of cases amenable to surgery at diagnosis. Local control for unresectable tumours can be provided with external beam radiotherapy. The aim of this retrospective study is to describe the safety and efficacy of stereotactic body radiation therapy (SBRT) for treatment of canine thyroid carcinoma. Twenty-three dogs met inclusion criteria; median tumour volume before SBRT was 129.9 cm3 (range, 2.7-452.8 cm3 ). Sixteen patients (70%) had unresectable tumours. Pulmonary metastasis was present or suspected in 10 patients (44%) before SBRT. Patients were prescribed 15 to 40 Gy to targeted tumour volume in one to five fractions. Twenty patients evaluated had overall response rate of 70% (complete response, n = 4; partial response, n = 10). Thirteen out of sixteen (81%) symptomatic patients had clinical improvement within a median time of 16 days (range, 2-79 days). Median progression free survival (MPFS) was 315 days. Median survival time (MST) was 362 days. Nine patients (39%) had grade 1 acute radiation toxicity. Three patients had grade 1 late radiation toxicity (two leukotrichia and one [4%] with intermittent cough). Responders had significantly longer MPFS (362 vs 90 days; HR 4.3; 95% CI 1.4-13.5; P = .013) and MST (455 vs 90 days; HR 2.9; 95% CI 1-8.4; P = .053). Presenting with metastasis was not a significant negative prognostic factor (MST 347 vs 348 days without metastasis; P = .352). SBRT is a safe and effective treatment modality for non-resectable canine thyroid carcinoma.
Collapse
|
54
|
Chatelus E, Poindron V, Canuet M, Korganow AS, Germain P, Martin T, El Ghannudi S. SAT0309 CARDIAC MAGNETIC RESONANCE IMAGING ELEVATED NATIVE MYOCARDIAL T1 IS PREDICTIVE FOR THE DEVELOPMENT OF MYOCARDIAL DYSFUNCTION IN SYSTEMIC SCLEROSIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:All patients included in the study fulfilled the ACR/EULAR classification criteria for SSc. We prospectively included patients who underwent at least two CMR at 1.5T, including native T1 and T2 mapping (which give account for myocardial fibrosis and myocardial edema respectively), left and right ventricles morphology and functional assessment, and Late Gadolinium Enhancement (LGE) as a part of routine follow-up between 2015 and 2019.Objectives:To evaluate the prognostic value of initial abnormal T1 mapping.Methods:All patients included in the study fulfilled the ACR/EULAR classification criteria for SSc. We prospectively included patients who underwent at least two CMR at 1.5T, including native T1 and T2 mapping (which give account for myocardial fibrosis and myocardial edema respectively), left and right ventricles morphology and functional assessment, and Late Gadolinium Enhancement (LGE) as a part of routine follow-up between 2015 and 2019.Results:Sixty-three patients underwent at list two CMR during the study period. Forty-three patients were women. Mean age was 52.5±15.5 years old. Follow-up duration between the initial and the follow-up CMR was 14.5±11.5 months. Forty-one had diffuse SSc. The mean native T1 was 1066.8 ±44.6 ms. Twenty-one patients suffered from cardiac clinical manifestations. Nine patients died during the follow-up. Thirty patients (47.6%) had elevated T1 (ET1) with mean T1 1105.4±36.7 ms at the time of initial CMR. Initial ET1 was clearly correlated with: 1/ alteration of Left Ventricle (LV) Ejection fraction (EF) (r=0.5, p<0.0001) during the study period, 2/LV dilatation at initial screening and follow up (r=0.22, p=0.03 and r=0.3, p=0.02). Regarding Right ventricle, initial ET1 was correlated with initial Right Ventricle (RV) dilatation (r=0.3, p=0.02) but neither with RV volume nor RVEF at follow-up. Interestingly, initial ET1 correlated with pericardial effusion (r=0.3, p=0.003) which is known to be a pejorative prognostic factor. Seventeen patients (28%) had LGE but the ET1 at initial screening and follow-up was not correlated with LGE.Six patients had elevated T2 (ET2) which correlated with initial and follow up LV dilatation (r=0,32, p=0.002 and r=0.5, p<0.0001 respectively) but not with LVEF during the period study. Among other parameters, initial increased BNP was correlated with follow up ET1 LVEF and RVEF (r=0.4, p=0.01; r=0.35, p=0.007; r=0,37, p=0.005 respectively). In the same way, initial Pulmonary Arterial Hypertension (PAH) was correlated with follow up ET1 (r=0.3, p=0.02). Initial ET1 did not correlate with age, sex, cardiovascular risk factors, cardiac manifestations or death.Conclusion:Assessment of diffuse myocardial fibrosis by native T1 is predictive of the occurrence of cardiac dysfunction at the follow-up as initial ET1 was associated with decreased left ventricular function and LV and RV dilatations). These data highlights the potential role of CMR with T1mapping in initial screening and at the follow-up and provides new insights in the cardiac SSc follow up strategy.References:[1]Poindron V, Chatelus E, Canuet M, Gottenberg JE, Arnaud L, Gangi A, Gavand PE, Guffroy A, Korganow AS, Germain P, Sibilia J, El Ghannudi S, Martin T.T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients.Semin Arthritis Rheum. 2019 Jun 19.Disclosure of Interests:None declared
Collapse
|
55
|
Mertz P, Chalayer E, Sibilia J, Gottenberg JE, Korganow AS, Arnaud L, Martin T. AB1049 CLINICAL SPECTRUM AND THERAPEUTIC MANAGEMENT OF AUTO-IMMUNE MYELOFIBROSIS: A NATION-WIDE STUDY OF 30 CASES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.998] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Little is known about autoimmune myelofibrosis (AIMF), a rare entity that can occur alone or in association with another autoimmune disease (AID) and is responsible for bone marrow (BM) failure and life-threatening complications.Objectives:We conducted a nationwide retrospective observational study of AIMF cases to better characterize the epidemiology, clinical presentation and evolution of this rare entity.Methods:The aim of the study was to analyze the characteristics of AIMF and the nature and indication of treatments currently used. Response to treatment was evaluated by the revised Tefferi et al. response criteria.Results:Among 30 cases of AIMF, the sex ratio (F/M) was 4:1 and the median age at diagnosis was 37 years (interquartile range 30–49). AIMF was diagnosed after the onset of an associated AID in 12 cases and concomitant to an AID in the remaining 18 cases. The most frequently associated AID was systemic lupus erythematous, followed by Sjögren syndrome. All cases consisted of reticulin fibers, and no collagen fibrosis was described. More than 50% of cases showed complete response after first-line therapy, with glucocorticoids (GC) in 28 cases. Half of the cases had treatment complications mainly related to GC therapy.Conclusion:Diagnosis of AIMF remains challenging in the absence of a validated set of diagnosis criteria, and must always be searched in the presence of hematological abnormalities at onset or during follow-up of AID. Clinical context, search for mutations and pathology findings can help differentiating this rare disease from a clonal pathology. GC is currently an effective first-choice therapy for AIMF, but a high rate of GC dependency and long-term complications indicate the need to find new sparing drugs.Disclosure of Interests:PHILIPPE MERTZ: None declared, Emilie Chalayer: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg Grant/research support from: BMS, Pfizer, Consultant of: BMS, Sanofi-Genzyme, UCB, Speakers bureau: Abbvie, Eli Lilly and Co., Roche, Sanofi-Genzyme, UCB, Anne-Sophie Korganow: None declared, Laurent Arnaud: None declared, Thierry Martin: None declared
Collapse
|
56
|
Mertz P, Kleinmann JF, Lambert M, Puéchal X, Martin T, Sibilia J, Arnaud L. AB0510 INFLIXIMAB IS AN EFFECTIVE GLUCOCORTICOID-SPARING TREATMENT FOR TAKAYASU ARTERITIS: RESULTS OF A MULTICENTER OPEN-LABEL PROSPECTIVE STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Approximately half of patients with Takayasu Arteritis (TA) have glucocorticoid (GC)-dependency and require the addition of a second-line immunosuppressive treatment.Objectives:Here, we conducted a multicenter open-label prospective cohort study to assess the efficacy and safety of infliximab originator as a GC-sparing agent in TA.Methods:A temporary recommendation for use for infliximab in refractory TA was approved by the French National Drug Authorities (April 2014). Infliximab was administered to patients in case of disease activity with a NIH score ≥2 despite conventional therapy. Data regarding patient’s clinical, laboratory, imaging and treatments were obtained at baseline, and at each following visit until last visit (October 2017). TA activity was evaluated according to NIH criteria and GC requirement throughout the study.Results:Twenty-three patients were enrolled, including 19 female. The median age at inclusion was 33 years (Interquartile range, IQR: 23-44 years). At baseline, 17 (74%) patients were treated with GCs, at a median dose of 10 mg/day (IQR: 0-21) of prednisone-equivalent. After a median follow-up of 36.9 months (IQR: 10-58.7), improvement of ≥1 NIH criterion of TA activity was achieved for 14/22 (64%) patients. The median GC dose was 8 mg/day (IQR: 7-10) at 6 months; 5 mg/day (IQR: 0-8) at 12 months and 0 mg/day (IQR: 0-5) at 36 months of follow-up. Overall, infliximab originator had a significant GC-sparing effect between baseline and last follow-up (p=0.009).Conclusion:This multicenter open-label cohort study suggests that infliximab originator is an effective GC-sparing treatment for TA refractory to conventional therapy.Disclosure of Interests:None declared
Collapse
|
57
|
Levy D, Nespola B, Giannini M, Felten R, Varoquier C, Rinagel M, Korganow AS, Poindron V, Martin T, Maurier F, Chereih H, Bouldoires B, Hervier B, Lenormand C, Arnaud L, Geny B, Sibilia J, Gottenberg JE, Meyer A. FRI0249 IN MYOSITIS PATIENTS, SJÖGREN’S SYNDROME IS ASSOCIATED WITH INCLUSION BODY MYOSITIS AND WITH ANTI-CN1A ANTIBODIES INDEPENDENTLY OF THE MYOSITIS SUBTYPE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Myositis are characterized by weakness and muscle inflammation. They encompass heterogeneous conditions, which include dermatomyositis (DM), inclusion body myositis (IBM) and polymyositis (PM) according to the EULAR/ACR 2017 criteria. We recently recorded a high prevalence of IBM in a cohort of primary Sjögren’s syndrome (SS) (1). The signification of SS in the setting of myositis is unanswered.Objectives:To refine the signification of SS in the setting of myositis.Methods:Among a monocentric myositis cohort (according to the EULAR/ACR 2017 criteria), SS patients (according to the ACR/EULAR 2016 criteria) were identified (myositis/SS+ group) and compared to myositis patients without SS (myositis/SS- group).Results:Among 414 myositis patients, SS criteria were available for 96 patients. Thirty two (33%) presented SS. Patients with SS tended to be more frequently women (F/M ratio 9.7 vs 3.0, p = 0.07). Age at diagnosis of myositis was similar in both groups (53 years [range 21-74] vs 53 years [range 16-77], p = 0.51).Myositis subtypes repartition (as defined by EULAR/ACR 2017 criteria) was different in myositis/SS+ and myositis/SS- groups (p = 0.021), IBM being four-fold more prevalent in myositis/SS+ group (25% vs 6%, p = 0.018). Accordingly, the delay between the first muscle symptoms and myositis diagnosis was longer in myositis/SS+ group (7 months [0-336] vs 4 months [0-122], p = 0.041). Moreover, aside anti-cN1A antibodies, myositis-specific antibodies were less frequently found in myositis/SS+ patients than in myositis/SS- ones (16/32 [50%] vs 46/64 [72%], p = 0.035).Anti-cN1A antibodies were more prevalent in myositis/SS+ patients (33% vs 5.8%, p = 0.0032). However, in myositis/SS+ group, anti-cN1A were frequent in each of the EULAR/ACR 2017 myositis subtypes and the association between SS and anti-cN1A positivity was maintained in a multivariate analysis adjusted with the diagnosis of IBM (p = 0.023).Seven of the myositis/SS+ patients (22%) had systemic involvement typical of SS (vs 6 [9%] of the myositis/SS- patients, p = 0.12) including polyneuropathy (6 [20%] vs 6 [10%]) and type 2 cryoglobulinaemic vasculitis (1 [3%] vs 1 [1.6%]). In addition, 2 (6%) myositis/SS+ patients developed a lymphoma (one B diffuse large cell lymphoma of the parotid and one non-Hodgkin lymphoma), vs none of the myositis/SS- patients (p = 0.11). Only one (3%) of the myositis/SS+ patients developed myositis-associated cancer (diagnosed within 3 years of myositis diagnosis) versus 6 (9%) of the myositis/SS- patients (p = 0.66).Aside hydroxychloroquine, more frequently used in myositis/SS+ group (38% vs 16%, p = 0.018), no significant difference was found in the management of the patients (taking into account the myositis subtype).Conclusion:Myositis patients with SS have more frequently IBM than myositis patients without SS. They also have more frequently anti-cN1A antibodies, independently of the myositis subtype. They might develop systemic complications of SS.References:[1]Felten R, Seror R, Vittecoq O, Hachulla E, Perdriger A, Dieude P, et al. SAT0470 Myositis, often suspected, is actually rare in primary Sjögren’s syndrome: data from the French cohort ASSESS. In BMJ Publishing Group Ltd and European League Against Rheumatism; 2018. p. 1093.1–1093. Available from:http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-eular.2945Disclosure of Interests:Dan LEVY: None declared, Benoit Nespola: None declared, Margherita Giannini: None declared, Renaud FELTEN: None declared, Coralie Varoquier: None declared, Marina Rinagel: None declared, Anne-Sophie Korganow: None declared, Vincent Poindron: None declared, Thierry Martin: None declared, Francois Maurier: None declared, Hassam Chereih: None declared, Bastien Bouldoires: None declared, Baptiste Hervier: None declared, Cédric Lenormand: None declared, Laurent Arnaud: None declared, Bernard Geny: None declared, Jean Sibilia: None declared, Jacques-Eric Gottenberg Grant/research support from: BMS, Pfizer, Consultant of: BMS, Sanofi-Genzyme, UCB, Speakers bureau: Abbvie, Eli Lilly and Co., Roche, Sanofi-Genzyme, UCB, alain meyer: None declared
Collapse
|
58
|
Aguilar M, Ali Cavasonza L, Ambrosi G, Arruda L, Attig N, Barao F, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bindi V, de Boer W, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Burmeister S, Cai XD, Capell M, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen HS, Chen Y, Cheng L, Chou HY, Chouridou S, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Dai YM, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Freeman C, Galaktionov Y, Gámez C, García-López RJ, Gargiulo C, Gast H, Gebauer I, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guo KH, Haino S, Han KC, Hashmani RK, He ZH, Heber B, Hsieh TH, Hu JY, Huang ZC, Incagli M, Jang WY, Jia Y, Jinchi H, Kanishev K, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Kuhlman A, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li M, Li Q, Li S, Li TX, Li ZH, Light C, Lin CH, Lippert T, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo JZ, Lyu SS, Machate F, Mañá C, Marín J, Marquardt J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Molero M, Mott P, Mussolin L, Ni JQ, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Piandani R, Plyaskin V, Poluianov S, Qi XM, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Reina Conde A, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, Schmidt SM, Schulz von Dratzig A, Schwering G, Seo ES, Shan BS, Shi JY, Siedenburg T, Solano C, Sonnabend R, Song JW, Sun Q, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wallmann C, Wang LQ, Wang NH, Wang QL, Wang S, Wang X, Wang ZX, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yi H, Yu YJ, Yu ZQ, Zannoni M, Zhang C, Zhang F, Zhang FZ, Zhang JH, Zhang Z, Zhao F, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P. Properties of Neon, Magnesium, and Silicon Primary Cosmic Rays Results from the Alpha Magnetic Spectrometer. PHYSICAL REVIEW LETTERS 2020; 124:211102. [PMID: 32530660 DOI: 10.1103/physrevlett.124.211102] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Accepted: 04/20/2020] [Indexed: 06/11/2023]
Abstract
We report the observation of new properties of primary cosmic rays, neon (Ne), magnesium (Mg), and silicon (Si), measured in the rigidity range 2.15 GV to 3.0 TV with 1.8×10^{6} Ne, 2.2×10^{6} Mg, and 1.6×10^{6} Si nuclei collected by the Alpha Magnetic Spectrometer experiment on the International Space Station. The Ne and Mg spectra have identical rigidity dependence above 3.65 GV. The three spectra have identical rigidity dependence above 86.5 GV, deviate from a single power law above 200 GV, and harden in an identical way. Unexpectedly, above 86.5 GV the rigidity dependence of primary cosmic rays Ne, Mg, and Si spectra is different from the rigidity dependence of primary cosmic rays He, C, and O. This shows that the Ne, Mg, and Si and He, C, and O are two different classes of primary cosmic rays.
Collapse
|
59
|
Couffignal C, Kolta S, Flamant M, Cazanave C, Haymann JP, Mentré F, Duval X, Leport C, Raffi F, Chêne G, Salamon R, Moatti JP, Pierret J, Spire B, Brun-Vézinet F, Fleury H, Masquelier B, Peytavin G, Garraffo R, Costagliola D, Dellamonica P, Katlama C, Meyer L, Salmon D, Sobel A, Cuzin L, Dupon M, Le Moing V, Marchou B, May T, Morlat P, Rabaud C, Waldner-Combernoux A, Hardel L, Reboud P, Couffin-Cadiergues S, Marchand L, Assuied A, Carrieri P, Habak S, Couturier F, Jadand C, Perrier A, Préau M, Protopopescu C, Schmit J, Chennebault J, Faller J, Magy-Bertrand N, Chirouze C, Humbert P, Longy-Boursier, Neau D, Granier P, Ansart S, Verdon R, Merrien D, Chevojon P, Sobel A, Levy Y, Piroth L, Perronne C, Froguel E, Ceccaldi J, Chidiac C, Grégoire V, Reynes J, Fuzibet JG, Arsac P, Bouvet E, Bricaire F, Monsonego J, Girard P, Guillevin L, Herson S, Molina J, Pialoux G, Sain O, Sellier P, Roblot F, Bani-Sadr F, Michelet C, Lucht F, Debord C, Martin T, De Jaureguiberry J, Bernard L. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy. AIDS Res Hum Retroviruses 2020; 36:399-405. [PMID: 31891665 DOI: 10.1089/aid.2019.0229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
We assessed bone mineral density (BMD) in a cohort of human immunodeficiency virus (HIV)-positive patients after a median of 11 years of combination antiretroviral therapy (cART) and evaluated the respective role of HIV infection and antiretroviral drugs (ARVs). A cross-sectional study of 162 participants (131 male) from the ANRS-C08 cohort was performed with bone dual-energy X-ray absorptiometry (DXA) scans and renal assessment. The window of exposure to ARVs was defined as an exposure of more than six cumulative months during the last 3 years before the DXA evaluation to account for a cumulative exposure that could affect bone remodeling. The association with low BMD (Z-score < -2) was assessed by a multiple logistic regression model. The study population was 50 years (median), hepatitis C virus (HCV) (18%), and hepatitis B virus (HBV) (8%) coinfection with HIV-RNA <50 c/mL in 89%, median CD4 of 619/mm3. Prevalence of low BMD was 18% in males and 6% in females. The factors associated with a Z-score < -2 in males were uric acid renal loss [adjusted odds ratio (aOR): 6.1; 95% confidence interval (CI): 1.2-31.5; p = .03], HCV coinfection (aOR: 4.0; 95% CI: 1.3-12.2; p = .02), and less frequent window of exposure to nevirapine (NVP) (aOR: 0.1; 95% CI: 0.02-0.6; p = .01). For the full study sample, there was a strong positive association between duration of exposure to NVP and lumbar spine Z-score (p = .004). HIV-positive patients exposed to long-term cART have a high incidence of low BMD. Tenofovir disoproxil fumarate and ritonavir-boosted protease inhibitors did not seem to be associated with increased risk of low BMD, whereas NVP exposure appeared to have an independent positive association.
Collapse
|
60
|
Chouhan R, Higginson J, Martin T. Confidential image transfer: an ethico-legal dilemma. Br J Oral Maxillofac Surg 2020; 58:478-480. [PMID: 32165046 DOI: 10.1016/j.bjoms.2020.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 02/13/2020] [Indexed: 11/28/2022]
Abstract
Clinical photographs aid decision-making and represent important medicolegal records. Storage and transfer of images of the facial area must adhere to Caldicott Principles. Outside working hours, clinical photography services are often limited. Our Trust has introduced a Secure Clinical Image Transfer (SCIT) app allowing clinicians to take photographs on personal devices to be securely uploaded to the patient's electronic health record. To evaluate whether clinicians were taking clinical images in an insecure manner, clinicians completed an anonymous questionnaire before and after introduction of the SCIT app. The standard was 100% knowledge of, and adherence to, trust information governance guidelines. Response rate was 100% in both cycles. Introduction of the SCIT app reduced inappropriate clinical photography on personal devices. Our completed audit cycle shows that the SCIT app allows convenient, secure information capture on personal devices and automatic secure synchronisation to trust electronic health records.
Collapse
|
61
|
Ng Y, Bei B, Grima N, Cahill F, Martin T, Lo T, Rajaratnam S, Mansfield D. Cognitive behavioural therapy for insomnia in a multidisciplinary sleep clinic: participation rates and effectiveness. Sleep Med 2019. [DOI: 10.1016/j.sleep.2019.11.778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
62
|
Lefèvre G, Leurs A, Gibier J, Staumont-Sallé D, Dezoteux F, Chenivesse C, Terriou L, Hachulla E, Launay D, Labalette M, Quéméneur T, Hatron P, Schleinitz N, Viallard J, Hamidou M, Martin T, Morati-Hafsaoui C, Groh M, Lambert M, Kahn J. La vascularite à éosinophiles : une autre manifestation du syndrome hyperéosinophilique ? Analyse détaillée de 117 cas chez des patients non asthmatiques et sans ANCA. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
63
|
Bertolino J, Jouve E, Skopinski S, Agard C, Achille A, Thoreau B, Diot E, Sanges S, Berthier S, Chaigne B, Regent A, Martin T, Pugnet G, Benyamine A, Rossi P, Launay D, Mouthon L, Granel B. Caractéristiques des patients atteints de sclérodermie systémique souffrant d’une amputation d’un segment d’un membre inférieur. Étude collaborative au sein du GFRS. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
64
|
Mantey K, Cortaredona S, Martin T, Daniel L, Clément C, Karsenty G, Pascal L. Geographic disparities in bladder cancer incidence among women in the department of Bouches-du-Rhône. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz186.640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
While the incidence of bladder cancer begins to decline in men it increases in women related to tobacco smoking. The study aimed to describe bladder cancer among women in the department of Bouches-du-Rhône and assess their spatial distribution in order to detect potential spatial clusters. Cancer incidence data were obtained from the departmental observatory of cancers REVELA13. The characteristics of the cases registered were compared to those describe at the national level. Age-standardized incidence ratios (SIRs) were calculated for each commune and bayesian smoothed risk estimate based on the Besag, York and Mollie model were computed for incidence mapping. The spatial scan statistic (SaTScan) was used to investigate local cluster. Spatial analyses were adjusted on various confounding factors as a French deprivation index, access to health-care services and population density.
During the period 2013-2016, 395 cases of bladder cancers were diagnosed in women. Departmental incidence was significantly higher (3.3 cases per 100.000 inhabitants) than the national incidence (2.3). Compared to men, bladder cancers among women were diagnosed at a more advanced stage of the disease (p < 0.01). SIRs geographical variations were related to access of care but none of the communes showed any significant excess of cases. However, one significant cluster including nine districts of the biggest city (Marseille) and one neighbouring commune (RR = 1.76) was detected in the south east of the department.
Spatial studies of bladder cancer in women rarely find over-incidence or clusters due to lack of power. However, this study has shown that geographical disparities exist in particular because of a lesser access to a specialist. Regarding the high prevalence of smoking among women in the south of France, practitioners need to think about bladder cancer in women with urinary signs.
Key messages
We identify for the first time a cluster of bladder cancers in women in France. Practitioners need to think about bladder cancers in women with urinary signs because this cancer will become a public health issue in the future.
Collapse
|
65
|
Martin T, Bernuz B, De Brier G, Lenne-Aurier K, Tournebise H, Boissier R, Gaillet S, Lechevallier E, Perrin J, Karsenty G. Prise en charge de la fertilité des blessés médullaires : étude monocentrique de 2002 à 2018. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
66
|
Aguilar M, Ali Cavasonza L, Ambrosi G, Arruda L, Attig N, Bachlechner A, Barao F, Barrau A, Barrin L, Bartoloni A, Başeğmez-du Pree S, Battiston R, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bindi V, de Boer W, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Cai XD, Capell M, Caroff S, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen HS, Chen Y, Cheng L, Chou HY, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Cui Z, Dadzie K, Dai YM, Datta A, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Díaz C, Dimiccoli F, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Feng J, Fiandrini E, Fisher P, Formato V, Galaktionov Y, Gámez C, García-López RJ, Gargiulo C, Gast H, Gebauer I, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guo KH, Haino S, Han KC, He ZH, Hsieh TH, Huang H, Huang ZC, Incagli M, Jang WY, Jia Y, Jinchi H, Kanishev K, Khiali B, Kim GN, Kirn T, Konyushikhin M, Kounina O, Kounine A, Koutsenko V, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Li JQ, Li Q, Li TX, Li ZH, Light C, Lin CH, Lippert T, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo F, Luo JZ, Luo X, Lyu SS, Machate F, Mañá C, Marín J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Molero M, Mott P, Mussolin L, Nelson T, Ni JQ, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Phan HD, Plyaskin V, Poireau V, Poluianov S, Popkow A, Qi XM, Qin X, Qu ZY, Quadrani L, Rancoita PG, Rapin D, Reina Conde A, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Schael S, Schmidt SM, Schulz von Dratzig A, Schwering G, Seo ES, Shan BS, Shi JY, Siedenburg T, Solano C, Song JW, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Tüysüz C, Urban T, Usoskin I, Vagelli V, Vainio R, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Wang LQ, Wang NH, Wang QL, Wang X, Wang XQ, Wang ZX, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yi H, Yu YJ, Yu ZQ, Zannoni M, Zeissler S, Zhang C, Zhang F, Zhang JH, Zhang Z, Zhao F, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P. Properties of Cosmic Helium Isotopes Measured by the Alpha Magnetic Spectrometer. PHYSICAL REVIEW LETTERS 2019; 123:181102. [PMID: 31763896 DOI: 10.1103/physrevlett.123.181102] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 10/02/2019] [Indexed: 06/10/2023]
Abstract
Precision measurements by the Alpha Magnetic Spectrometer (AMS) on the International Space Station of ^{3}He and ^{4}He fluxes are presented. The measurements are based on 100 million ^{4}He nuclei in the rigidity range from 2.1 to 21 GV and 18 million ^{3}He from 1.9 to 15 GV collected from May 2011 to November 2017. We observed that the ^{3}He and ^{4}He fluxes exhibit nearly identical variations with time. The relative magnitude of the variations decreases with increasing rigidity. The rigidity dependence of the ^{3}He/^{4}He flux ratio is measured for the first time. Below 4 GV, the ^{3}He/^{4}He flux ratio was found to have a significant long-term time dependence. Above 4 GV, the ^{3}He/^{4}He flux ratio was found to be time independent, and its rigidity dependence is well described by a single power law ∝R^{Δ} with Δ=-0.294±0.004. Unexpectedly, this value is in agreement with the B/O and B/C spectral indices at high energies.
Collapse
|
67
|
Jäger KRK, Luo ZX, Martin T. Postcranial Skeleton of Henkelotherium guimarotae (Cladotheria, Mammalia) and Locomotor Adaptation. J MAMM EVOL 2019. [DOI: 10.1007/s10914-018-09457-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
68
|
Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat Commun 2019; 10:1486. [PMID: 30940805 PMCID: PMC6445096 DOI: 10.1038/s41467-019-09415-3] [Citation(s) in RCA: 176] [Impact Index Per Article: 35.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Accepted: 03/06/2019] [Indexed: 12/22/2022] Open
Abstract
Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kinase inhibitor that has exceptional antineoplastic activity when combined with non-ICD inducing chemotherapeutics like cisplatin. The combination of cisplatin and high-dose crizotinib induces ICD in non-small cell lung carcinoma (NSCLC) cells and effectively controls the growth of distinct (transplantable, carcinogen- or oncogene induced) orthotopic NSCLC models. These anticancer effects are linked to increased T lymphocyte infiltration and are abolished by T cell depletion or interferon-γ neutralization. Crizotinib plus cisplatin leads to an increase in the expression of PD-1 and PD-L1 in tumors, coupled to a strong sensitization of NSCLC to immunotherapy with PD-1 antibodies. Hence, a sequential combination treatment consisting in conventional chemotherapy together with crizotinib, followed by immune checkpoint blockade may be active against NSCLC. Certain chemotherapeutic agents can exert their anticancer effect through indirect immune-dependent mechanism. Here, the authors screen a library of tyrosine kinase inhibitors and show that crizotinib is an effective stimulator of immunogenic cell death and can potentiate the efficacy of immune checkpoint blockade.
Collapse
|
69
|
Cunnane K, Alvarado A, Gwak Y, Peters C, Romero-Sandoval E, Martin T, Eisenach J. (247) Studying Pain Neural Circuits with Viral Vector rAAV2-Retro in the Brain. THE JOURNAL OF PAIN 2019. [DOI: 10.1016/j.jpain.2019.01.169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
70
|
Aguilar M, Ali Cavasonza L, Alpat B, Ambrosi G, Arruda L, Attig N, Azzarello P, Bachlechner A, Barao F, Barrau A, Barrin L, Bartoloni A, Basara L, Başeğmez-du Pree S, Battiston R, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bindi V, de Boer W, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Cai XD, Capell M, Caroff S, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen HS, Chen Y, Cheng L, Chou HY, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Crispoltoni M, Cui Z, Dadzie K, Dai YM, Datta A, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Di Felice V, Dimiccoli F, Díaz C, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Eronen T, Feng J, Fiandrini E, Fisher P, Formato V, Galaktionov Y, García-López RJ, Gargiulo C, Gast H, Gebauer I, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guo KH, Haino S, Han KC, He ZH, Heil M, Hsieh TH, Huang H, Huang ZC, Incagli M, Jia Y, Jinchi H, Kanishev K, Khiali B, Kirn T, Konak C, Kounina O, Kounine A, Koutsenko V, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Leluc C, Li JQ, Li Q, Li TX, Li ZH, Light C, Lin CH, Lippert T, Liu FZ, Liu H, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo F, Luo JZ, Luo X, Lyu SS, Machate F, Mañá C, Marín J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Molero M, Mott P, Mussolin L, Nelson T, Ni JQ, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Perrina C, Phan HD, Picot-Clemente N, Plyaskin V, Pohl M, Poireau V, Popkow A, Quadrani L, Qi XM, Qin X, Qu ZY, Rancoita PG, Rapin D, Conde AR, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Solano C, Schael S, Schmidt SM, von Dratzig AS, Schwering G, Seo ES, Shan BS, Shi JY, Siedenburg T, Song JW, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Urban T, Vagelli V, Valente E, Valtonen E, Acosta MV, Vecchi M, Velasco M, Vialle JP, Vizán J, Wang LQ, Wang NH, Wang QL, Wang X, Wang XQ, Wang ZX, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yi H, Yu YJ, Yu ZQ, Zannoni M, Zeissler S, Zhang C, Zhang F, Zhang JH, Zhang Z, Zhao F, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P. Towards Understanding the Origin of Cosmic-Ray Electrons. PHYSICAL REVIEW LETTERS 2019; 122:101101. [PMID: 30932626 DOI: 10.1103/physrevlett.122.101101] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Indexed: 06/09/2023]
Abstract
Precision results on cosmic-ray electrons are presented in the energy range from 0.5 GeV to 1.4 TeV based on 28.1×10^{6} electrons collected by the Alpha Magnetic Spectrometer on the International Space Station. In the entire energy range the electron and positron spectra have distinctly different magnitudes and energy dependences. The electron flux exhibits a significant excess starting from 42.1_{-5.2}^{+5.4} GeV compared to the lower energy trends, but the nature of this excess is different from the positron flux excess above 25.2±1.8 GeV. Contrary to the positron flux, which has an exponential energy cutoff of 810_{-180}^{+310} GeV, at the 5σ level the electron flux does not have an energy cutoff below 1.9 TeV. In the entire energy range the electron flux is well described by the sum of two power law components. The different behavior of the cosmic-ray electrons and positrons measured by the Alpha Magnetic Spectrometer is clear evidence that most high energy electrons originate from different sources than high energy positrons.
Collapse
|
71
|
Baboudjian M, Lechevallier E, Michel F, Ben Othman K, Martin T, Di Crocco E, Akiki A, Gaillet S, Delaporte V, Karsenty G, Boissier R. [Does diagnostic ureterorenoscopy increase the risk of bladder recurrence after total nephroureterectomy? A review of the literature]. Prog Urol 2019; 29:138-146. [PMID: 30846356 DOI: 10.1016/j.purol.2019.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 11/04/2018] [Accepted: 02/01/2019] [Indexed: 10/27/2022]
Abstract
OBJECTIVE The objective of our study was to evaluate, in a review of the literature, the impact of diagnostic ureteroscopy before total nephroureterectomy (NUT) on the risk of bladder recurrence. METHODS We conducted a literature review in the Pubmed database in March 2018. Initial research identified 45 publications. Following full text screening, 9 studies were finally included, with a total of 1041 NUT with URS prior versus 2909 NUT alone. The primary endpoint was bladder recurrence. Secondary objectives were specific survival and overall survival. RESULTS Bladder recurrence was reported in the 9 studies included. Diagnostic ureteroscopy was significantly associated with an increased risk of post-NUT bladder recurrence (HZ 1.42 [1.29-1.56], P<0.01). The specific survival and overall survival at 5 years, were reported in respectively 4 and 2 studies. There was no impact of the pre-NUT diagnostic URS on the specific survival (HZ 0.75 [0.54-1.03], P=0.08) or post-NUT overall survival (HZ 1.15 [0.68-1.96], P=0.59). CONCLUSION The URS diagnostic before NUT for TVEUS is associated with a significant increase in the risk of postoperative bladder recurrence.
Collapse
|
72
|
Jonckheere T, Rech J, Zazunov A, Egger R, Yeyati AL, Martin T. Giant Shot Noise from Majorana Zero Modes in Topological Trijunctions. PHYSICAL REVIEW LETTERS 2019; 122:097003. [PMID: 30932546 DOI: 10.1103/physrevlett.122.097003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Indexed: 06/09/2023]
Abstract
The clear-cut experimental identification of Majorana bound states in transport measurements still poses experimental challenges. We here show that the zero-energy Majorana state formed at a junction of three topological superconductor wires is directly responsible for giant shot noise amplitudes, in particular at low voltages and for small contact transparency. The only intrinsic noise limitation comes from the current-induced dephasing rate due to multiple Andreev reflection processes.
Collapse
|
73
|
Corneloup M, Maurier F, Wahl D, Muller G, Aumaitre O, Sève P, Blaison G, Pennaforte JL, Martin T, Magy-Bertrand N, Berthier S, Arnaud L, Bourredjem A, Amoura Z, Devilliers H. Réponses aux items des questionnaires spécifiques de qualité de vie dans les 18 mois suivant une poussée de lupus érythémateux systémique : une analyse en théorie de la réponse à l’item de la cohorte française EQUAL. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2018.11.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
74
|
Aguilar M, Ali Cavasonza L, Ambrosi G, Arruda L, Attig N, Azzarello P, Bachlechner A, Barao F, Barrau A, Barrin L, Bartoloni A, Basara L, Başeğmez-du Pree S, Battiston R, Becker U, Behlmann M, Beischer B, Berdugo J, Bertucci B, Bindi V, de Boer W, Bollweg K, Borgia B, Boschini MJ, Bourquin M, Bueno EF, Burger J, Burger WJ, Cai XD, Capell M, Caroff S, Casaus J, Castellini G, Cervelli F, Chang YH, Chen GM, Chen HS, Chen Y, Cheng L, Chou HY, Choutko V, Chung CH, Clark C, Coignet G, Consolandi C, Contin A, Corti C, Crispoltoni M, Cui Z, Dadzie K, Dai YM, Datta A, Delgado C, Della Torre S, Demirköz MB, Derome L, Di Falco S, Dimiccoli F, Díaz C, von Doetinchem P, Dong F, Donnini F, Duranti M, Egorov A, Eline A, Eronen T, Feng J, Fiandrini E, Fisher P, Formato V, Galaktionov Y, García-López RJ, Gargiulo C, Gast H, Gebauer I, Gervasi M, Giovacchini F, Gómez-Coral DM, Gong J, Goy C, Grabski V, Grandi D, Graziani M, Guo KH, Haino S, Han KC, He ZH, Heil M, Hsieh TH, Huang H, Huang ZC, Incagli M, Jia Y, Jinchi H, Kanishev K, Khiali B, Kirn T, Konak C, Kounina O, Kounine A, Koutsenko V, Kulemzin A, La Vacca G, Laudi E, Laurenti G, Lazzizzera I, Lebedev A, Lee HT, Lee SC, Leluc C, Li JQ, Li Q, Li TX, Li ZH, Light C, Lin CH, Lippert T, Liu FZ, Liu H, Liu Z, Lu SQ, Lu YS, Luebelsmeyer K, Luo F, Luo JZ, Luo X, Lyu SS, Machate F, Mañá C, Marín J, Martin T, Martínez G, Masi N, Maurin D, Menchaca-Rocha A, Meng Q, Mo DC, Molero M, Mott P, Mussolin L, Nelson T, Ni JQ, Nikonov N, Nozzoli F, Oliva A, Orcinha M, Palermo M, Palmonari F, Paniccia M, Pashnin A, Pauluzzi M, Pensotti S, Perrina C, Phan HD, Picot-Clemente N, Plyaskin V, Pohl M, Poireau V, Popkow A, Quadrani L, Qi XM, Qin X, Qu ZY, Rancoita PG, Rapin D, Conde AR, Rosier-Lees S, Rozhkov A, Rozza D, Sagdeev R, Solano C, Schael S, Schmidt SM, Schulz von Dratzig A, Schwering G, Seo ES, Shan BS, Shi JY, Siedenburg T, Song JW, Sun ZT, Tacconi M, Tang XW, Tang ZC, Tian J, Ting SCC, Ting SM, Tomassetti N, Torsti J, Urban T, Vagelli V, Valente E, Valtonen E, Vázquez Acosta M, Vecchi M, Velasco M, Vialle JP, Vizán J, Wang LQ, Wang NH, Wang QL, Wang X, Wang XQ, Wang ZX, Wei J, Weng ZL, Wu H, Xiong RQ, Xu W, Yan Q, Yang Y, Yi H, Yu YJ, Yu ZQ, Zannoni M, Zeissler S, Zhang C, Zhang F, Zhang JH, Zhang Z, Zhao F, Zheng ZM, Zhuang HL, Zhukov V, Zichichi A, Zimmermann N, Zuccon P. Towards Understanding the Origin of Cosmic-Ray Positrons. PHYSICAL REVIEW LETTERS 2019; 122:041102. [PMID: 30768313 DOI: 10.1103/physrevlett.122.041102] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/21/2018] [Revised: 12/04/2018] [Indexed: 06/09/2023]
Abstract
Precision measurements of cosmic ray positrons are presented up to 1 TeV based on 1.9 million positrons collected by the Alpha Magnetic Spectrometer on the International Space Station. The positron flux exhibits complex energy dependence. Its distinctive properties are (a) a significant excess starting from 25.2±1.8 GeV compared to the lower-energy, power-law trend, (b) a sharp dropoff above 284_{-64}^{+91} GeV, (c) in the entire energy range the positron flux is well described by the sum of a term associated with the positrons produced in the collision of cosmic rays, which dominates at low energies, and a new source term of positrons, which dominates at high energies, and (d) a finite energy cutoff of the source term of E_{s}=810_{-180}^{+310} GeV is established with a significance of more than 4σ. These experimental data on cosmic ray positrons show that, at high energies, they predominantly originate either from dark matter annihilation or from other astrophysical sources.
Collapse
|
75
|
Gorbenko V, Zorenko T, Paprocki K, Riva F, Douissard PA, Martin T, Zorenko Y. Epitaxial growth of single-crystalline-film scintillators based on Tb3+-doped and Tb3+–Ce3+-codoped Gd1–xLuxAlO3 (x = 0–1) mixed perovskites. CrystEngComm 2019. [DOI: 10.1039/c8ce01889h] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The paper is dedicated to the development of scintillating screens based on the single crystalline films of singly Tb3+ and doubly Tb3+–Ce3+ doped Gd1–xLuxAlO3 (x = 0–1) perovskites grown onto YAlO3 substrates using the liquid phase epitaxy method.
Collapse
|